Gregory Daniel Frank, PhD, is currently teaching human physiology in health and disease at UCSC Silicon Valley and consulting to biotech start-ups in a variety of therapeutic areas. Previously, he was director of business development at 23andMe where he worked on drug discovery collaborations, license agreements, and academic and industry partnerships. Prior to 23andMe, Gregory was vice president at Emergent Technologies in Austin, TX, with management responsibility for a number of portfolio companies including Pure MHC. Before Emergent, he was director of business development at XBiotech in Austin and previously spent 10 years in licensing and business development at SRI International in Menlo Park, CA.
Gregory has deep domain experience in biotech/pharma, medicine, and healthcare and has built strategic partnerships across all phases of development including research, preclinical, clinical, and direct to consumer. He received his PhD in Immunology from Stanford University School of Medicine and his BA in Biology from the University of California at Santa Cruz.
Clinical Adoption of Personalized Medicine: Challenges and Solutions
1:10 PM - 2:00 PM